ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial

CONCLUSIONS: In this multicenter phase I/II trial, we demonstrated that a 19 Gy single-fraction urethra-sparing SBRT is feasible and associated with an acceptable toxicity rate, mostly returning to the baseline at week-12 and with a symptoms flare between months 12 and 18. Longer follow-up is needed to assess the potential long-term adverse effects and the disease control efficacy.PMID:38403022 | DOI:10.1016/j.radonc.2024.110181

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - February 25, 2024 Category: Radiology Authors: Thomas Zilli Ciro Franzese Matthias Guckenberger Niccol ò Giaj-Levra Nicolas Mach Nikolaos Koutsouvelis Verane Achard Andrew McDonald Filippo Alongi Marta Scorsetti Guillaume Constantin Aurelie Bertaut Raymond Miralbell Source Type: research